Search USNA
USANA HEALTH SCIENCES INC
NYSE · CIK 896264
Last close14.82
Daily change+0.45 (3.13%)
10 Years gain-78.99%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
USNA · STANDARD
SIC 2833 · Medicinal Chemicals & Botanical Products · Fiscal year end 0103
Fundamental
33.4Momentum
15.0Acceleration
15.0Confidence
91.0Annual Revenue17
Quarterly Revenue70
Annual CFO17
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth1.1 / 25
Quality6.0 / 25
Capital Efficiency0.5 / 20
Balance Sheet15.0 / 15
Shareholder Economics9.1 / 10
Forward Indicators0.0 / 5
Signals
Share count reductionDiluted share count declined 3.1386%.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 2.737 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 7.0059 percentage points.
Key Metrics
Revenue Growth TTM3.66%OK
Revenue CAGR 3Y-2.51%OK
Gross Margin77.6%OK
Operating Margin1.28%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC2.17%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-3.14%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Jan 03, 2026 | $925.26M | $724.41M | $37.43M | $22.35M | $8.53M | 78.29% | 4.05% | 0.92% | 6.71% | 18.57M |
| 2025 FY Dec 28, 2024 | $854.50M | $693.29M | $66.32M | $60.99M | $50.92M | 81.13% | 7.76% | 5.96% | 16.67% | 19.16M |
| 2025 FY Dec 30, 2023 | $921.01M | $744.32M | $93.07M | $70.64M | $56.15M | 80.82% | 10.11% | 6.1% | 38.68% | 19.35M |
| 2023 FY Dec 31, 2022 | $998.60M | $804.71M | $107.61M | $103.90M | $93.50M | 80.58% | 10.78% | 9.36% | 46.42% | 19.31M |
| 2023 FY Jan 01, 2022 | $1.19B | $968.57M | $170.19M | $121.23M | $108.46M | 81.63% | 14.34% | 9.14% | 81.54% | 20.34M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $923.01M | sum latest 4 fiscal quarters Revenue | OK | 0000896264-26-000056, 0000896264-25-000224 |
| Revenue Growth TTM | 3.66% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000896264-26-000056, 0000896264-25-000224 |
| Revenue CAGR 3Y | -2.51% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000896264-26-000021 |
| Revenue CAGR 5Y | -4% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000896264-26-000021 |
| Gross Profit CAGR 3Y | -3.44% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000896264-26-000021 |
| Operating Income Growth | -83.98% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0000896264-26-000056, 0000896264-25-000224 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 77.6% | Gross Profit / Revenue | OK | 0000896264-26-000056, 0000896264-25-000224 |
| Operating Margin | 1.28% | Operating Income / Revenue | OK | 0000896264-26-000056, 0000896264-25-000224 |
| ROIC | 2.17% | NOPAT / Average Invested Capital | OK | 0000896264-26-000056, 0000896264-25-000224 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000896264-26-000056 |
| Current Ratio | 2.66x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $49.93 | Revenue / Diluted Shares | OK | 0000896264-26-000056, 0000896264-25-000224 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |